Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

value

- PMLiVE

Russian innovation at the crossroads

Despite improvements, investors face rising risks

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

- PMLiVE

Communicating value

The global recession has changed the way the industry needs to market its medicines

- PMLiVE

England’s Cancer Drugs Fund: Fixing a broken system

Following the culling of 16 medicines from the Fund PME looks at how to improve market access for new oncology products

Time to get personal about adherence

Patients must be offered support strategies based on their individual adherence barriers

Reconciling patient empowerment and EU regulations

To achieve true patient-centricity, regulatoryframeworks must be aligned with the real-world

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

The problem with pills

Conventional solid dosage forms have failed to keep pace with modern consumers’ evolving demands

- PMLiVE

Global pledge to immunise 300 million children

Commitment made at GAVI Pledging Conference follows criticism of high vaccine prices

- PMLiVE

Charity calls for universal liver health screening in UK

British Liver Trust will screen MPs as part of Love Your Liver campaign

- PMLiVE

Charity launches #SmearForSmear campaign

Jo's Cervical Cancer Trust aims to raise awareness of cancer screening

- PMLiVE

Pharma can learn to invent like an entrepreneur

Why pharma firms don’t always have to behave like corporations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links